secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066396
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals
--------------------------------------------------------------------------------

- Cash $677.5M; expects funding operations into H2 2026.
- R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.
- ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.
- DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.
- New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/0000950170-25-066396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/dyn-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer